Rituximab for Anticytokine Autoantibody-Associated Syndromes

利妥昔单抗治疗抗细胞因子自身抗体相关综合征

• 批准号: 10712564
• 负责人: Steven Holland
• 金额: $ 27.61万
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10712564
• 关键词: 18 year old; Affect; Antibodies; Antigens; Autoantibodies; Autoimmune Diseases; B-Lymphocyte Subsets; B-Lymphocytes; Blood; Bronchoscopy; CD40 Ligand; Candidiasis; Clinical; Disease; Endoscopy; Enrollment; Flow Cytometry; Granulocyte-Macrophage Colony-Stimulating Factor; Image; Immunologic Deficiency Syndromes; Immunologics; Infection; Infusion procedures; Interferon Type II; Interleukin-17; Intravenous infusion procedures; Laboratories; Mediator of activation protein; Methods; Monoclonal Antibody CD20; Mucocutaneous Candidiasis; Myasthenia Gravis; Mycobacterium Infections; Pathogenicity; Patients; Pemphigus Vulgaris; Process; Production; Progressive Disease; Pulmonary Alveolar Proteinosis; Quality of life; Refractory; Rheumatoid Arthritis; Safety; Surveys; Syndrome; Toxic effect; Visit; X-Ray Computed Tomography; anti-CD20; arm; base; conventional therapy; cytokine; follow-up; inflammatory marker; insight; non-tuberculosis mycobacteria; open label; phase I trial; rituximab; screening

Anti-cytokine autoantibodies have been shown to be an important mediator of certain serious diseases including immunodeficiency due to anti-IFNg autoantibodies and pulmonary alveolar proteinosis due to anti-GM-CSF autoantibodies. Some patients are refractory to optimized conventional therapy or have serious intolerance to standard approaches. We are enrolling patients with anticytokine autoantibody syndromes who have progressive disease despite optimized conventional treatment. We will treat patients and collect their blood and evaluate disease-affected regions however appropriate, i.e. imaging for anti-IFNg-autoantibody associated deep-seated infections, endoscopy for anti-IL-17-autoantibody-associated candidiasis, bronchoscopy and/or CT imaging for GM-CSF autoantibody associated pulmonary alveolar proteinosis. We will evaluate blood for changes in autoantibody levels using our luminex-based method for antibody screening, inflammatory markers using the clinical lab, and immunological parameters such as CD40 Ligand expression and B lymphocyte subsets using flow cytometry. We will also apherese patients prestudy and identify antigen-specific B cells (that recognize specific cytokines) by flow cytometry and ELIspot. We will also perform a quality of life survey pre and post study and clinically score disease activity to evaluate for evidence of efficacy.

抗细胞因子自身抗体已被证明是某些严重疾病的重要介质，包括由于抗IFNg自身抗体引起的免疫缺陷和由于抗GM-CSF自身抗体引起的肺泡蛋白沉积症。 一些患者对优化的常规治疗难治或对标准方法严重不耐受。 我们正在招募抗细胞因子自身抗体综合征患者，这些患者尽管接受了优化的常规治疗，但疾病仍进行性。 我们将治疗患者并收集其血液，并评估疾病影响区域，但适当的，即抗IFNg-自身抗体相关的深部感染的成像，抗IL-17-自身抗体相关的念珠菌病的内窥镜检查，GM-CSF自身抗体相关的肺泡蛋白沉积症的支气管镜检查和/或CT成像。 我们将使用基于Luminex的抗体筛查方法评估血液中自身抗体水平的变化，使用临床实验室评估炎症标志物，使用流式细胞术评估免疫学参数，如CD 40配体表达和B淋巴细胞亚群。 我们还将通过流式细胞术和ELIspot对单采患者进行预研究和鉴定抗原特异性B细胞（识别特定细胞因子）。 我们还将在研究前后进行生活质量调查，并对疾病活动进行临床评分，以评估疗效证据。